Compare KTTA & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTTA | ECPG |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 1.4B |
| IPO Year | N/A | 1999 |
| Metric | KTTA | ECPG |
|---|---|---|
| Price | $0.78 | $70.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $77.33 |
| AVG Volume (30 Days) | 96.5K | ★ 293.3K |
| Earning Date | 03-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 287.14 |
| EPS | N/A | ★ 10.91 |
| Revenue | N/A | ★ $1,768,802,000.00 |
| Revenue This Year | N/A | $3.63 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ N/A | $6.22 |
| Revenue Growth | N/A | ★ 34.37 |
| 52 Week Low | $0.28 | $26.45 |
| 52 Week High | $2.34 | $74.58 |
| Indicator | KTTA | ECPG |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 64.79 |
| Support Level | $0.67 | $54.39 |
| Resistance Level | $0.90 | $74.58 |
| Average True Range (ATR) | 0.05 | 2.57 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 28.90 | 60.83 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.